Zevra Therapeutics (ZVRA) Equity Average (2015 - 2026)

Zevra Therapeutics has reported Equity Average for 12 years, with the latest figure at $180.2 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 346.73% year-over-year to $180.2 million; the trailing twelve-month figure through Mar 2026 stood at $180.2 million (up 346.73% YoY), and the FY2025 full-year result was $97.2 million, up 91.39% from the prior year.
• Equity Average for Q1 2026 stood at $180.2 million, up from $143.9 million in the prior quarter.
• The five-year high for Equity Average was $267.0 million in Q1 2022, with the low at $40.3 million in Q1 2025.
• Historically, Equity Average has averaged $91.4 million across 5 years, with a median of $61.7 million in 2023.
• Annual changes were most pronounced in 2022 — Equity Average soared 2893.75% — and 2023, when it plunged 74.84%.
• Zevra Therapeutics' Equity Average stood at $84.5 million in 2022, then dropped by 26.95% to $61.7 million in 2023, then dropped by 11.31% to $54.7 million in 2024, then jumped by 163.0% to $143.9 million in 2025, then gained by 25.24% to $180.2 million in 2026.
• The last three Equity Average figures came in at $180.2 million (Q1 2026), $143.9 million (Q4 2025), and $125.2 million (Q3 2025), per Business Quant data.